Skip to main content

Secukinumab Dosage

Medically reviewed by Drugs.com. Last updated on Aug 15, 2023.

Applies to the following strengths: 150 mg/mL; 75 mg/0.5 mL; 300 mg/2 mL; 25 mg/mL

Usual Adult Dose for Plaque Psoriasis

300 mg subcutaneously at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks (each 300 mg dose is given as 2 subcutaneous injections of 150 mg); for some patients, a dose of 150 mg subcutaneously may be acceptable

Use: Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy

Usual Adult Dose for Psoriatic Arthritis

WITH A LOADING DOSE: 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
WITHOUT A LOADING DOSE: 150 mg subcutaneously every 4 weeks; if the patient continues to have active psoriatic arthritis, consider increasing the dose to 300 mg subcutaneously every 4 weeks

Comments:


Use: Active psoriatic arthritis

Usual Adult Dose for Ankylosing Spondylitis

WITH A LOADING DOSE: 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
WITHOUT A LOADING DOSE: 150 mg subcutaneously every 4 weeks

Uses:

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Reconstitution/preparation techniques:

Storage requirements:

General:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.